$170.00
Retatrutide is an investigational multi-receptor agonist developed for the treatment of obesity
and related metabolic disorders. It acts on three key receptors: GLP-1 (glucagon-like peptide-1),
GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, making it a
tri-agonist. By targeting these receptors, Retatrutide promotes weight loss, improves glycemic
control, and enhances energy expenditure. Early clinical studies have shown significant
reductions in body weight and improvements in metabolic health markers, suggesting its
potential as a powerful therapy for obesity, type 2 diabetes, and non-alcoholic fatty liver disease
(NAFLD). It is currently in the research and development phase.
nexgenresearch.com. All Rights Reserved.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Peptide Sciences is a chemical supplier. Peptide Sciences is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Peptide Sciences is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Reviews
There are no reviews yet.